References
1. Canadian Pharmacists Association. Compendium of Pharmaceuticals and
Specialties. Pantoprazole monograph. [ Available from:
https://www.pharmacists.ca ].
2. Shaheen NJ, Falk GW, Iyer PG, Gerson LB, American College of G. ACG
Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus.Am J Gastroenterol. 2016;111(1):30-50; quiz 51.
3. Barkun AN, Almadi M, Kuipers EJ, et al. Management of Nonvariceal
Upper Gastrointestinal Bleeding: Guideline Recommendations From the
International Consensus Group. Ann Intern Med. 2019.
4. Therapeutics Initiative. A Systematic Review of the Comparative
Effectiveness of Proton Pump Inhibitors for the Treatment of Adult
Patients with Gastroesophageal Reflux Disease or Peptic Ulcer Disease.
2016. [ Available from: https://ti.ubc.ca/derp-ppi
5. Therapeutics Initiative. Comparative Effectiveness of Proton Pump
Inhibitors. Therapeutics Letter 99. [ Available from:
https://www.ti.ubc.ca/2016/06/28/99.
6. Kinoshita Y, Ishimura N, Ishihara S. Advantages and Disadvantages of
Long-term Proton Pump Inhibitor Use. J Neurogastroenterol Motil.2018;24(2):182-196.
7. Jaynes M, Kumar AB. The risks of long-term use of proton pump
inhibitors: a critical review. Ther Adv Drug Saf.2019;10:2042098618809927.
8. Makunts T, Cohen IV, Awdishu L, Abagyan R. Analysis of postmarketing
safety data for proton-pump inhibitors reveals increased propensity for
renal injury, electrolyte abnormalities, and nephrolithiasis. Sci
Rep. 2019;9(1):2282.
9. Vaezi MF, Yang YX, Howden CW. Complications of Proton Pump Inhibitor
Therapy. Gastroenterology. 2017;153(1):35-48.
10. Government of Canada. Advisories, Warnings and Recalls – Drugs and
health products 2019 [Available from:
https://www.canada.ca/en/health-canada/services/drugs-health-products/advisories-warnings-recalls.html.
11. Canadian Association of Gastroenterology, Choosing Wisely Canada.
Gastroenterology–Five Things Physicians and Patients Should Question.
Last updated: June 2017.
https://choosingwiselycanada.org/gastroenterology/.
12. Farrell B, Pottie K, Thompson W, et al. Deprescribing proton pump
inhibitors: Evidence-based clinical practice guideline. Can Fam
Physician. 2017;63(5):354-364.
13. Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of Proton Pump
Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients
Receiving Rivaroxaban or Aspirin. Gastroenterology. 2019.
14. Boghossian TA, Rashid FJ, Thompson W, et al. Deprescribing versus
continuation of chronic proton pump inhibitor use in adults.Cochrane Database Syst Rev. 2017;3:CD011969.
15. Therapeutics Initiative. Trends in utilization of proton pump
inhibitors in British Columbia.Therapeutics Letter 118. [ Available
from: https://www.ti.ubc.ca/2019/04/15/118.
16. Griebling TL. Re: American Geriatrics Society 2019 Updated AGS Beers
Criteria(R) for Potentially Inappropriate Medication Use in Older
Adults. J Urol. 2019;202(3):438.
17. Shiraev TP, Bullen A. Proton Pump Inhibitors and Cardiovascular
Events: A Systematic Review. Heart Lung Circ. 2018;27(4):443-450.
18. Xie Y, Bowe B, Yan Y, Xian H, Li T, Al-Aly Z. Estimates of all cause
mortality and cause specific mortality associated with proton pump
inhibitors among US veterans: cohort study. BMJ. 2019;365:l1580.
19. Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of Proton Pump
Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients
Receiving Rivaroxaban or Aspirin. Gastroenterology.2019;157(3):682-691 e682.
20. Charlot M, Grove EL, Hansen PR, et al. Proton pump inhibitor use and
risk of adverse cardiovascular events in aspirin treated patients with
first time myocardial infarction: nationwide propensity score matched
study. BMJ. 2011;342:d2690.
21. Shiraev TP, Bullen A. Proton Pump Inhibitors and Cardiovascular
Events: A Systematic Review. Heart Lung Circ. 2018;27(4):443-450.
22. Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19
loss-of-function variants on the eradication of H. pylori infection in
patients treated with proton pump inhibitor-based triple therapy
regimens: a meta-analysis of randomized clinical trials. PLoS
ONE. 2013;8(4):e62162.
23. Yasuda H, Matsuo Y, Sato Y, et al. Treatment and prevention of
gastrointestinal bleeding in patients receiving antiplatelet therapy.World J Crit Care Med. 2015;4(1):40-46.
24. Yasuda H, Yamada M, Sawada S, et al. Upper gastrointestinal bleeding
in patients receiving dual antiplatelet therapy after coronary stenting.Intern Med. 2009;48(19):1725-1730.
25. Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant
drugs for the prevention and treatment of peptic ulcer disease and its
complications: a meta-analysis of randomised trials. Lancet
Gastroenterol Hepatol. 2018;3(4):231-241.
26. Hussain S, Singh A, Habib A, Najmi AK. Proton pump inhibitors use
and risk of chronic kidney disease: Evidence-based meta-analysis of
observational studies. Clinical Epidemiology and Global Health.2019;7(1):46-52.
27. Yepuri G, Sukhovershin R, Nazari-Shafti TZ, Petrascheck M, Ghebre
YT, Cooke JP. Proton Pump Inhibitors Accelerate Endothelial Senescence.Circulation research. 2016;118(12):e36-42.
28. Corsonello A, Lattanzio F, Bustacchini S, et al. Adverse Events of
Proton Pump Inhibitors: Potential Mechanisms. Curr Drug Metab.2018;19(2):142-154.
29. Sampathkumar K, Ramalingam R, Prabakar A, Abraham A. Acute
interstitial nephritis due to proton pump inhibitors. Indian J
Nephrol. 2013;23(4):304-307.
30. Yang Y, George KC, Shang WF, Zeng R, Ge SW, Xu G. Proton-pump
inhibitors use, and risk of acute kidney injury: a meta-analysis of
observational studies. Drug Des Devel Ther. 2017;11:1291-1299.
31. Lanas-Gimeno A, Hijos G, Lanas A. Proton pump inhibitors, adverse
events and increased risk of mortality. Expert Opin Drug Saf.2019;18(11):1043-1053.
32. World Health Organization. Essential medicines and health products.
Pharmacovigilance. Available from:
https://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/.
33. Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and
strengths of the disproportionality analysis for identification of
adverse drug reactions in a pharmacovigilance database. British
journal of clinical pharmacology. 2011;72(6):905-908.
34. Hernan MA, Robins JM. Using Big Data to Emulate a Target Trial When
a Randomized Trial Is Not Available. American journal of
epidemiology. 2016;183(8):758-764.
35. Benson K, Hartz AJ. A comparison of observational studies and
randomized, controlled trials. The New England journal of
medicine. 2000;342(25):1878-1886.
36. Mulder R, Singh AB, Hamilton A, et al. The limitations of using
randomised controlled trials as a basis for developing treatment
guidelines. Evidence-based mental health. 2018;21(1):4-6.
37. Schneeweiss S. Sensitivity analysis and external adjustment for
unmeasured confounders in epidemiologic database studies of
therapeutics. Pharmacoepidemiol Drug Saf. 2006;15(5):291-303.
38. Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Risk of death among
users of Proton Pump Inhibitors: a longitudinal observational cohort
study of United States veterans. BMJ Open. 2017;7(6):e015735.